Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Biologically active products of complement and acute lung injury in patients with the sepsis syndrome.

Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, Murray JF.

Am Rev Respir Dis. 1984 Nov;130(5):791-6.

PMID:
6497161
2.

The effects of methylprednisolone on complement-mediated neutrophil activation during cardiopulmonary bypass.

Tennenberg SD, Bailey WW, Cotta LA, Brodt JK, Solomkin JS.

Surgery. 1986 Aug;100(2):134-42.

PMID:
3738745
3.

Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease.

Gardinali M, Padalino P, Vesconi S, Calcagno A, Ciappellano S, Conciato L, Chiara O, Agostoni A, Nespoli A.

Arch Surg. 1992 Oct;127(10):1219-24.

PMID:
1417490
4.
5.

Complement levels in septic primates treated with anti-C5a antibodies.

Hangen DH, Stevens JH, Satoh PS, Hall EW, O'Hanley PT, Raffin TA.

J Surg Res. 1989 Mar;46(3):195-9.

PMID:
2493531
6.

Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.

Marder SR, Chenoweth DE, Goldstein IM, Perez HD.

J Immunol. 1985 May;134(5):3325-31.

PMID:
3884709
7.

Purification of human C5a des arg by immunoadsorbent and molecular sieve chromatography.

Manderino GL, Suarez AF, Kunkel SL, Ward PA, Hirata AA, Showell H.

J Immunol Methods. 1982 Aug 27;53(1):41-50.

8.

Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.

Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, Raffin TA.

J Clin Invest. 1986 Jun;77(6):1812-6.

9.
11.

Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts.

Senior RM, Griffin GL, Perez HD, Webster RO.

J Immunol. 1988 Nov 15;141(10):3570-4.

PMID:
3183381
12.

Regulation of neutrophil migratory function in burn injury by complement activation products.

Solomkin JS, Nelson RD, Chenoweth DE, Solem LD, Simmons RL.

Ann Surg. 1984 Dec;200(6):742-6.

13.

Airways hyperreactivity and inflammation produced by aerosolization of human C5A des arg.

Irvin CG, Berend N, Henson PM.

Am Rev Respir Dis. 1986 Oct;134(4):777-83.

PMID:
3767132
15.
16.

Mechanisms of loss of human neutrophil chemotaxis following thermal injury.

Nelson RD, Hasslen SR, Ahrenholz DH, Solem LD.

J Burn Care Rehabil. 1987 Nov-Dec;8(6):496-502.

PMID:
3436972
17.

Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin.

Takematsu H, Tagami H.

Arch Dermatol. 1993 Jan;129(1):74-80.

PMID:
8420495
19.

Rapid and simple measurement of human C5a-des-Arg level in plasma or serum using monoclonal antibodies.

Takeda J, Kinoshita T, Takata Y, Kozono H, Tanaka E, Hong K, Inoue K.

J Immunol Methods. 1987 Aug 3;101(2):265-70.

PMID:
3611800
20.

Terminal complement complexes and anaphylatoxins in septic and ischemic patients.

Heideman M, Norder-Hansson B, Bengtson A, Mollnes TE.

Arch Surg. 1988 Feb;123(2):188-92.

PMID:
3277584

Supplemental Content

Support Center